Korea Reimburses Zolgensma Amid Wider Cost Management Initiatives
Executive Summary
Zolgensma becomes the second Novartis gene therapy - and highest-priced therapeutic product - to be reimbursed in South Korea, prompting authorities to come up with plans to manage expensive therapies to ensure the sustainability of the national health insurance system.
You may also be interested in...
MSD Exec On Progress, Complexity Of HTA For Keytruda In Asia-Pacific
MSD’s Global Medical Affairs Lead, Asia Pacific, Aileen Dualan, discusses in an interview with Scrip the diverse, multi-faceted HTA and reimbursement landscape for cancer therapies like Keytruda in the APAC region and progress made, among other issues.
International Horizon Scanning Initiative Moves Forward
An initiative that will improve payers’ ability to negotiate prices for disruptive new drugs is closer to fruition.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.